AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02949349
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Provided as 250mg/capsule, dose specific for each arm, orally twice a day, for 24 weeks.
Trial: NCT00653393
Drug: Tranylcypromine
RxNorm normalized name: Tranylcypromine
DrugBank: Tranylcypromine (DB00752)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 10 mg, single-dose
Trial: NCT00653393
Drug: Parnate
RxNorm normalized name: Parnate
DrugBank: Tranylcypromine (DB00752)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 10 mg, single-dose
Trial: NCT00119457
Drug: TTP889
RxNorm normalized name: TTP889
DrugBank: TTP889 (DB05131)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04041453
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin at 600mcg/kg in addition to albendazole will be provided for 1 or 3 days.
Trial: NCT04041453
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.
Trial: NCT03294694
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)
Trial: NCT03294694
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each treatment cycle lasts 28 days. Fulvestrant will be administered during Cycle 1 on days 1 and 15, and then on day 1 of each 28-day cycle thereafter.
Trial: NCT01233167
Drug: clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: clopidogrel 75 mg po per day for 12 months
Trial: NCT01233167
Drug: clopidogrel and placebo
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: clopidogrel 50mg per day for 3 months,clopidogrel 25mg per day for 3 months,then placebo 75mg per day for 6 months
Trial: NCT00003241
Drug: phenylacetate
RxNorm normalized name: phenylacetate
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04602494
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: varenicline: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
Trial: NCT03635372
Drug: Alginate
RxNorm normalized name: Alginate
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 cc of Alginate peroral
Trial: NCT03635372
Drug: Sucralfate
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 cc of Sucralfate peroral
Trial: NCT03635372
Drug: Hydrotalcite
RxNorm normalized name: Hydrotalcite
DrugBank: Hydrotalcite (DB13322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 cc of Hydrotalcite peroral
Trial: NCT03428568
Drug: Nexium
RxNorm normalized name: Nexium
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: omeprazole
Trial: NCT03428568
Drug: Amoxil
RxNorm normalized name: Amoxil
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic
Trial: NCT02253524
Drug: Dimenhydrinate
RxNorm normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg Dramamine with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
Trial: NCT02253524
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
Trial: NCT02688933
Drug: HOE901-U300 (Insulin Glargine 300 U/ml)
RxNorm normalized name: insulin glargine 300 UNT/ML
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.
Trial: NCT02688933
Drug: Lantus (Insulin Glargine 100 U/ml)
RxNorm normalized name: insulin glargine 100 UNT/ML [Lantus]
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.
Trial: NCT02688933
Drug: Mandated back ground therapy
RxNorm normalized name: Pep-Back
DrugBank: Date (DB10632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
Trial: NCT00535652
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: powder for infusion, 1 gram I.V., single dose over 30 min.
Trial: NCT02012725
Drug: Arm 1 MRI with gadolinium
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers will not receive gadolinium
Trial: NCT00098241
Drug: Certican
RxNorm normalized name: Bordetella pertussis toxoid vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Certiva]
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03844776
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: paracetamol orally
Trial: NCT03844776
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine mouthwash
Trial: NCT02287038
Drug: Atomoxetine 80 MG
RxNorm normalized name: atomoxetine 80 MG
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized and assigned by the study investigator into crossover group 1 (Atomoxetine 80mg at Phase I, then placebo at Phase II) or group 2 (placebo at Phase I, then Atomoxetine at Phase II) with both placebo and medication administered through pharmacy. There was a 1-week interval between the two phases.
Trial: NCT03724357
Drug: Vaxchora
RxNorm normalized name: Vaxchora
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose. Approximately 100 mL of cold or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
Trial: NCT04405323
Drug: Lu AG06466
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard capsules, orally, single doses
Trial: NCT04405323
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 and 300 mg, capsules, orally
Trial: NCT01623921
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
Trial: NCT02249104
Drug: Adapalene/benzoyl peroxide gel, 0.1%/2.5%
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical AV therapy
Trial: NCT00919633
Drug: interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous continuous infusion at one of three doses for 48 weeks
Trial: NCT00919633
Drug: peginterferon alfa-2b
RxNorm normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 μg/kg subcutaneous weekly for 48 weeks
Trial: NCT00919633
Drug: ribavirin, USP
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive oral ribavirin
Trial: NCT00564941
Drug: deferasirox
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01699724
Drug: sertraline ODT
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg tablet on Day 1 of each period
Trial: NCT00652847
Drug: ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ezetimibe 10 mg/day for a six week course of treatment.
Trial: NCT00652847
Drug: statins
RxNorm normalized name: Endostatins
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase
Trial: NCT03374839
Drug: TIL + IL-2 + Nivolumab
RxNorm normalized name: IL-2
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The patients will receive Nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks from day0 until week52.~Two TIL (Tumor Infiltrating Lymphocytes) injections will be performed: at week 14 and at week 18.~The TIL injections are systematically followed by subcutaneous injections of Proleukin® (IL-2) at a concentration of 6 million international unit (IU) per day for 5 days.
Trial: NCT03117634
Drug: Treat and Extend with Aflibercept 2mg
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug treatment regime which allows extension of treatment interval based on disease activity
Trial: NCT03117634
Drug: Fixed Dosing with Aflibercept 2mg
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed 8 weekly dosing regime throughout the study duration
Trial: NCT01919164
Drug: Sprifermin
RxNorm normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received Sprifermin as intra-articular injection.
Trial: NCT00458315
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00458315
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00458315
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00458315
Drug: Avastin (Bevacizumab)
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03844776
Drug: Amoxicillin 500 Mg
RxNorm normalized name: amoxicillin 500 MG
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 orally
Trial: NCT00830505
Drug: fluticasone/salmeterol
RxNorm normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 puffs twice a day for 2 weeks
Trial: NCT00830505
Drug: fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs twice a day for 2 weeks
Trial: NCT01334424
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance
Trial: NCT01935960
Drug: Retinoid 9cUAB30
RxNorm normalized name: RETINOID 9CUAB30
DrugBank: 9CUAB30 (DB12316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03338881
Drug: TAK-659
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-659 tablets.
Trial: NCT00062595
Drug: menatetranone (MK4)
RxNorm normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02323178
Drug: eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: initial dose of 50 mg once daily, then the dose can be sequentially increased every 2 weeks up to a maximum dose of 300mg/day
Trial: NCT00685906
Drug: Levonorgestrel and Ethinyl Estradiol (Nordette®)
RxNorm normalized name: estradiol / ethinyl estradiol / levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet taken by mouth once a day for 28 days per cycle
Trial: NCT00733187
Drug: ABT-869
RxNorm normalized name: ABT-925
DrugBank: ABT-639 (DB15055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg
Trial: NCT00262145
Drug: tea extracts
RxNorm normalized name: green tea extract
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04520503
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose of propofol required for loss of consciousness and the total induction dose of propofol will be recorded for every patients.
Trial: NCT04942769
Drug: Selenium
RxNorm normalized name: Selenium
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selenium 100ug ，take it orally twice daily
Trial: NCT02079480
Drug: BMS-986090
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02100839
Drug: AEM-28
RxNorm normalized name: AEM-28
DrugBank: AEM-28 (DB17642)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection
Trial: NCT00018824
Drug: NALTREXONE
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01543568
Drug: aflibercept 2.0 mg
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal aflibercept injection 2.0 mg
Trial: NCT03844776
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metronidazole 500 mg orally
Trial: NCT01204099
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01204099
Drug: PX-866
RxNorm normalized name: PX-102
DrugBank: PX-102 (DB15416)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02079480
Drug: Keyhole limpet hemocyanin
RxNorm normalized name: Keyhole limpet hemocyanin
DrugBank: Keyhole limpet hemocyanin (DB05299)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04787887
Drug: Abcertin
RxNorm normalized name: Alcortin
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 60IU/kg Single Intravenous Administration
Trial: NCT00664352
Drug: Mannose-6-Phosphate (Juvidex)
RxNorm normalized name: Recombinant human acid alpha-glucosidase optimized for high expression of mannose 6-phosphate
DrugBank: Mannose (DB12907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 100µL of 300mM (8.46 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.
Trial: NCT00664352
Drug: Mannose-6-Phosphate (Juvidex)
RxNorm normalized name: Recombinant human acid alpha-glucosidase optimized for high expression of mannose 6-phosphate
DrugBank: Mannose (DB12907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 100µL of 600mM(16.93 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.
Trial: NCT00664352
Drug: Mannose-6-Phosphate (Juvidex)
RxNorm normalized name: Recombinant human acid alpha-glucosidase optimized for high expression of mannose 6-phosphate
DrugBank: Mannose (DB12907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.
Trial: NCT00104182
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01044225
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
Trial: NCT01044225
Drug: Cilengitide EMD 121974
RxNorm normalized name: Emdisterone
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of 2000 mg by IV administration 2 weekly.
Trial: NCT02660060
Drug: Pramipexole Dexa Medica
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.25 tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals as the test drug.
Trial: NCT00664352
Drug: Mannose-6-Phophate (Juvidex)
RxNorm normalized name: Mannose 6-phosphate
DrugBank: Mannose (DB12907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.
Trial: NCT02660060
Drug: Pramipexole Boehringer Ingelheim Pharma
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.25 tablets produced by Boehringer Ingelheim Pharma GmbH \& Co.KG for Boehringer Ingelheim International GmbH as the reference drug.
Trial: NCT01795794
Drug: omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02262650
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02262650
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02154932
Drug: 2 doses 400 microgram misoprostol
RxNorm normalized name: misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 doses 400 microgram misoprostol, 3 and 1 hours
Trial: NCT02154932
Drug: single dose misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 dose, 1 hours, prior surgery
Trial: NCT00405171
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01912820
Drug: quercetin
RxNorm normalized name: Quercetin
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00498680
Drug: Sildenafil, Vardenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.
Trial: NCT00498680
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg
Trial: NCT00498680
Drug: Vardenafil
RxNorm normalized name: Vardenafil
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg
Trial: NCT00498680
Drug: Sildenafil & Vardenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg \& 10 mg
Trial: NCT01051921
Drug: CTS-1027
RxNorm normalized name: CTS-1027
DrugBank: CTS-1027 (DB08490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTS-1027 supplied in 5 and 10 mg tablets, 15 mg taken twice daily, for up to 48 weeks
Trial: NCT01051921
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon, 180 micrograms in 0.5 ml of solution injected subcutaneously (SQ) once per week, for up to 48 weeks. Packaged in single use syringes.
Trial: NCT01051921
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin, 200 mg capsules taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg for up to 48 weeks.
Trial: NCT00699777
Drug: Risedronate
RxNorm normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 risedronate 150 mg tablet administered orally
Trial: NCT00699777
Drug: Risedronate
RxNorm normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 risedronate 75 mg tablets administered as a single oral dose